{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:07:45Z","timestamp":1791140865639,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.humpath.2012.08.002","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T14:28:01Z","timestamp":1351520881000},"page":"777-785","source":"Crossref","is-referenced-by-count":19,"title":["Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance"],"prefix":"10.1016","volume":"44","author":[{"given":"Thea Eline","family":"Hetland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag Andre","family":"Nymoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arild","family":"Holth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti","family":"Brusegard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi Ann","family":"Fl\u00f8renes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"K\u00e6rn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes G.","family":"Trop\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.humpath.2012.08.002_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0020-7292(03)90118-4","article-title":"Carcinoma of the ovary","volume":"83","author":"Heintz","year":"2003","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.humpath.2012.08.002_bb0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00001622-200209000-00008","article-title":"Management of recurrent ovarian cancer: evidence based decisions","volume":"14","author":"Salom","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/BJ20100284","article-title":"How protein kinases co-ordinate mitosis in animal cells","volume":"435","author":"Ma","year":"2011","journal-title":"Biochem J"},{"key":"10.1016\/j.humpath.2012.08.002_bb0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrc1526","article-title":"Aurora-A\u2014a guardian of poles","volume":"5","author":"Marumoto","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2012.08.002_bb0025","first-page":"1420","article-title":"Activation and overexpression of centrosome kinase BTAK\/Aurora-A in human ovarian cancer","volume":"9","author":"Gritsko","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.08.002_bb0030","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1158\/1078-0432.CCR-09-3171","article-title":"Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2","volume":"16","author":"Yang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.08.002_bb0035","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/1078-0432.CCR-07-0671","article-title":"DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma","volume":"13","author":"Kulkarni","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.08.002_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","article-title":"AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol","volume":"3","author":"Anand","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2012.08.002_bb0045","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1158\/1078-0432.CCR-06-2775","article-title":"Predictive value of Aurora-A\/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy","volume":"13","author":"Lassmann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.08.002_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2010.09.003","article-title":"Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma","volume":"120","author":"Lassus","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0055","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-07-0431","article-title":"Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients","volume":"13","author":"Landen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2012.08.002_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.humpath.2008.10.011","article-title":"Aurora kinases as prognostic biomarkers in ovarian carcinoma","volume":"40","author":"Mendiola","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0065","first-page":"60","article-title":"The Aurora kinase family in cell division and cancer","volume":"1786","author":"Vader","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.humpath.2012.08.002_bb0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00428-009-0838-3","article-title":"Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients","volume":"455","author":"Chen","year":"2009","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2012.08.002_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jclinpath-2011-200212","article-title":"Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma","volume":"65","author":"Beussel","year":"2012","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1158\/1535-7163.MCT-09-0765","article-title":"Aurora kinase inhibitors\u2014rising stars in cancer therapeutics?","volume":"9","author":"Dar","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2012.08.002_bb0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.bbagrm.2010.09.004","article-title":"Aurora kinase inhibitors as anticancer molecules","volume":"1799","author":"Katayama","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.humpath.2012.08.002_bb0090","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.humpath.2012.08.002_bb0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1615\/CritRevOncog.v13.i3.10","article-title":"Biological characteristics of cancers involving the serosal cavities","volume":"13","author":"Davidson","year":"2007","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.humpath.2012.08.002_bb0100","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/00000478-200111000-00008","article-title":"The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells","volume":"25","author":"Davidson","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2012.05.029","article-title":"MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival","volume":"126","author":"Hetland","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0110","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2012.08.002_bb0120","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.humpath.2009.09.017","article-title":"Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma","volume":"41","author":"Bunkholt Elstrand","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0125","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.humpath.2008.10.019","article-title":"Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma","volume":"40","author":"Kleinberg","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.22426","article-title":"Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma","volume":"109","author":"Kleinberg","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2012.08.002_bb0135","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.humpath.2010.10.025","article-title":"Class III \u03b2-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance","volume":"42","author":"Hetland","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/dc.20879","article-title":"Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors","volume":"36","author":"Kleinberg","year":"2008","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0145","doi-asserted-by":"crossref","first-page":"149362","DOI":"10.1155\/2010\/149362","article-title":"A current review of targeted therapeutics for ovarian cancer","volume":"2010","author":"Campos","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.humpath.2012.08.002_bb0150","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrc2964","article-title":"Shared and separate functions of polo-like kinases and aurora kinases in cancer","volume":"10","author":"Lens","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2012.08.002_bb0155","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3109\/00313025.2010.508789","article-title":"Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers","volume":"42","author":"Das","year":"2010","journal-title":"Pathology"},{"key":"10.1016\/j.humpath.2012.08.002_bb0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/PGP.0b013e31820d20ba","article-title":"Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites","volume":"30","author":"K\u00f6bel","year":"2011","journal-title":"Int J Gynecol Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771200281X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771200281X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T19:27:36Z","timestamp":1542655656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681771200281X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S004681771200281X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2012.08.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}